MYO

Business Context and Reporting Period

Company: MYOMO, INC. (NYSE American: MYO)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Myomo is a wearable medical robotics company developing the MyoPro, a myoelectric-controlled upper limb orthosis for patients with neuromuscular disorders (e.g., stroke, spinal cord injury). The company primarily operates through a "direct billing" channel, providing devices directly to patients and billing insurance payers, though it also sells to Orthotics and Prosthetics (O&P) providers, the Veterans Administration (VA), and international markets.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 26% year-over-year, driven by a higher number of revenue units and a higher average selling price. Direct billing revenue grew 20% to $30.4 million, while International revenue surged 48% to $6.8 million.
• Margin Compression: Gross margin declined 5.5 percentage points to 65.7%, attributed to unfavorable changes in overhead capitalization and higher warranty expenses.
• Expense Increases: Operating expenses rose 40% to $41.3 million. Selling, clinical, and marketing expenses jumped 67% due to increased advertising spend and headcount. R&D expenses increased 46% to support the development of the MyoPro 3.
• Debt Financing: In November 2025, the company entered a $17.5 million term loan facility with Avenue Capital Management. The first tranche of $12.5 million was funded to repay prior debt with Silicon Valley Bank and for general corporate purposes.
• Backlog Dynamics: Despite revenue growth, the backlog of authorized but undelivered units decreased 27% to 199 units, indicating improved operational velocity and faster revenue recognition cycles.

Guidance, Outlook, and Risks

Management Commentary and Outlook

Management plans to pivot in 2026 away from reliance on direct-to-patient advertising toward recurring revenue sources, specifically the "MyoConnect" referral program and expansion of the O&P channel in the U.S. and Germany. The company aims to reduce the Cost Per Pipeline Add and minimize fixed expense growth. Management believes current cash and the new debt facility are sufficient to fund operations for the next 12 months.

Key Risks and Contingencies

• Reimbursement Concentration: 54% of 2025 revenue came from Medicare Part B patients. Adverse changes in CMS policies or Medicare Advantage plan authorizations (which have been reducing authorizations since late 2024) pose a significant risk.
• China Joint Venture: The company's Chinese partner, Ryzur Medical, filed for bankruptcy in November 2025. Operations of the joint venture are severely limited, though the company has already written off associated assets.
• Cybersecurity: A ransomware attack on a third-party service provider in February 2026 may have exposed company data; the materiality is currently undetermined.
• Debt Covenants: The new loan agreement includes strict covenants regarding minimum cash balances ($2.5 million), revenue targets (75% of trailing three-month projections), and cash burn limits.

Investor Verification Checklist

• Cash Runway: Verify if the $18.4 million cash balance and $12.5 million funded debt tranche are sufficient to sustain operations given the $14.5 million operating cash burn in 2025.
• Medicare Advantage Trends: Monitor the trend of pre-authorizations from Medicare Advantage plans, as denials and reduced authorizations have negatively impacted revenue velocity.
• China JV Resolution: Track the restructuring efforts of the China joint venture to determine if any future revenue or strategic value can be recovered.
• Debt Covenant Compliance: Assess the company's ability to meet the specific revenue and cash burn covenants required by the Avenue Capital loan agreement.
• Cost Per Pipeline Add: Evaluate the effectiveness of the new "MyoConnect" program in lowering customer acquisition costs compared to the previous direct-to-consumer advertising model.